Cumulative Disease Control with Upadacitinib in Moderate-to-Severe Atopic Dermatitis—A 52-Week Multicenter Real-World Study: IL-AD (Italian Landscape Atopic Dermatitis)

INTRODUCTION: Fixed-timepoint endpoints may not fully capture longitudinal treatment benefit in atopic dermatitis (AD). We evaluated the 52-week real-world effectiveness and safety of upadacitinib, focusing on cumulative disease control. METHODS: This multicenter retrospective analysis of prospectively collected LANDSCAPE registry data included patients with moderate-to-severe AD receiving stable upadacitinib 15 mg or 30 mg once daily. Patients who underwent dose modification from 15 to 30 mg or from 30 to 15 mg during the 52-week observation period were excluded from the present analysis to ensure that longitudinal outcomes and cumulative disease-control estimates could be consistently attributed to a stable upadacitinib dose. Outcomes were assessed at baseline and weeks 16, 32, and 52. Moderate disease control was defined as EASI75 plus peak pruritus numerical rating scale (pp-NRS) ≤ 4, and optimal disease control/minimal disease activity (MDA) as EASI90 plus pp-NRS ≤ 1. Cumulative control was estimated as equivalent days in target using a time-in-target approach. RESULTS: Overall, 433 patients were included; 315 (72.7%) received 15 mg and 118 (27.3%) received 30 mg. At week 52, EASI75 and EASI90 were achieved by 85.7% and 72.7% of patients, respectively; moderate and optimal disease control/MDA were achieved by 80.6% and 62.6%. Patients spent a mean of 253.3 ± 101.9 equivalent days in moderate disease control and 176.1 ± 124.4 days in optimal control/MDA. Sustained moderate and optimal disease control from weeks 16 to 52 were achieved by 63.0% and 38.3%, respectively. Overall, 27.0% experienced at least one adverse event, with no permanent treatment discontinuations due to adverse events. CONCLUSION: Upadacitinib provided sustained real-world disease control over 52 weeks. Time-in-target measures may complement conventional endpoints by better reflecting persistence of therapeutic benefit.

Authors

Institutions

Publication Details

Journal
Dermatology and Therapy
Published
2026-10-15
DOI
https://doi.org/10.1007/s13555-026-01958-w
Primary Topic
Dermatology and Skin Diseases
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Cumulative Disease Control with Upadacitinib in Moderate-to-Severe Atopic Dermatitis—A 52-Week Multicenter Real-World Study: IL-AD (Italian Landscape Atopic Dermatitis)

Diego Orsini, Luca Mastorino, Marco Campoli, Manfredi Magliulo et al.
Dermatology and Therapy
Dermatology and Skin Diseases
article

Cumulative Disease Control with Upadacitinib in Moderate-to-Severe Atopic Dermatitis—A 52-Week Multicenter Real-World Study: IL-AD (Italian Landscape Atopic Dermatitis)

Diego Orsini, Luca Mastorino, Marco Campoli, Manfredi Magliulo, Martina Maurelli, Angelo Valerio Marzano, Simone Ribero, Massimo Gola, Maddalena Napolitano, Francesco Loconsole, Maria Esposito, Eugenia Veronica Di Brizzi, Giampiero Girolomoni, Mariateresa Rossi, Chiara Assorgi, Ruggero Cascio Ingurgio, Mario Bruno Guanti, Antonio Costanzo, Anna Balato, Luca Potestio, Maria Concetta Fargnoli, Stefano Bighetti, Michela Ortoncelli, Elena Pezzolo, Cataldo Patruno, Anna Graziella Burroni, Pietro Morrone, Andrea Carugno, Nicola Zerbinati, Marco Romanelli, Silvia Mariel Ferrucci, Antonio Podo Brunetti, Francesca Maria Gaiani, Francesca Barei, Franco Rongioletti, Francesco Messina, Matteo Bianco, Giulia Carpentieri, Narcisi Alessandra, Francesca di Vico, Mattia Cristallo, Raul Armando Luyo Saboya, Eustachio Nettis, Anna Francesca Cavaliere, Piergiorgio Malagoli, Flavia Manzo Margiotta
article en

Abstract

INTRODUCTION: Fixed-timepoint endpoints may not fully capture longitudinal treatment benefit in atopic dermatitis (AD). We evaluated the 52-week real-world effectiveness and safety of upadacitinib, focusing on cumulative disease control. METHODS: This multicenter retrospective analysis of prospectively collected LANDSCAPE registry data included patients with moderate-to-severe AD receiving stable upadacitinib 15 mg or 30 mg once daily. Patients who underwent dose modification from 15 to 30 mg or from 30 to 15 mg during the 52-week observation period were excluded from the present analysis to ensure that longitudinal outcomes and cumulative disease-control estimates could be consistently attributed to a stable upadacitinib dose. Outcomes were assessed at baseline and weeks 16, 32, and 52. Moderate disease control was defined as EASI75 plus peak pruritus numerical rating scale (pp-NRS) ≤ 4, and optimal disease control/minimal disease activity (MDA) as EASI90 plus pp-NRS ≤ 1. Cumulative control was estimated as equivalent days in target using a time-in-target approach. RESULTS: Overall, 433 patients were included; 315 (72.7%) received 15 mg and 118 (27.3%) received 30 mg. At week 52, EASI75 and EASI90 were achieved by 85.7% and 72.7% of patients, respectively; moderate and optimal disease control/MDA were achieved by 80.6% and 62.6%. Patients spent a mean of 253.3 ± 101.9 equivalent days in moderate disease control and 176.1 ± 124.4 days in optimal control/MDA. Sustained moderate and optimal disease control from weeks 16 to 52 were achieved by 63.0% and 38.3%, respectively. Overall, 27.0% experienced at least one adverse event, with no permanent treatment discontinuations due to adverse events. CONCLUSION: Upadacitinib provided sustained real-world disease control over 52 weeks. Time-in-target measures may complement conventional endpoints by better reflecting persistence of therapeutic benefit.

Dermatology and Therapy
University of Pisa (IT), University of Insubria (IT), University of Verona (IT), University of Modena and Reggio Emilia (IT), University of Molise (IT), Humanitas University (IT), Vita-Salute San Raffaele University (IT), University of Milan (IT), University of Campania "Luigi Vanvitelli" (IT), University of L'Aquila (IT), Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (IT), Azienda Universitaria Ospedaliera Consorziale - Policlinico Bari (IT), Saint Camillus International University of Health and Medical Sciences (IT), Azienda Ospedaliera di Cosenza (IT), Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia (IT), Federico II University Hospital (IT), IRCCS Ospedale San Raffaele (IT), Ospedale Policlinico San Martino (IT), Ospedale San Bortolo (IT), IRCCS Humanitas Research Hospital (IT), University of Florence (IT), University of Turin (IT), University of Bari Aldo Moro (IT), University of Naples Federico II (IT), University of Genoa (IT), Sapienza University of Rome (IT), Icahn School of Medicine at Mount Sinai (US)
Good health and well-being
Openalex Percentile: Top 10%
Dermatology and Skin Diseases
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.